Growth hormone deficiency after localized ganglioneuroblastoma: A case report

J Pediatr Hematol Oncol. 2006 Sep;28(9):625-6. doi: 10.1097/01.mph.0000212984.51867.88.

Abstract

Growth hormone deficiency (GHD) related to standard dose chemotherapy has rarely been described. We report on a case of localized ganglioneuroblastoma treated by carboplatin/etoposide for 2 courses and surgery, which developed a serious GHD after 56 months. At present, the child is growing on by GH replacement therapy. We discuss about the hypothesis that GHD may be related to chemotherapy and we report a review of previous published cases.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Gland Neoplasms / drug therapy*
  • Adrenal Gland Neoplasms / surgery
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Body Height / drug effects
  • Carboplatin / adverse effects
  • Etoposide / adverse effects
  • Ganglioneuroblastoma / drug therapy*
  • Ganglioneuroblastoma / surgery
  • Growth Hormone / deficiency*
  • Humans
  • Hypothalamus / drug effects
  • Hypothalamus / pathology
  • Infant
  • Male
  • Pituitary Gland / drug effects
  • Pituitary Gland / pathology

Substances

  • Etoposide
  • Growth Hormone
  • Carboplatin